FDA Uses FHIR to Transform Drug Data Exchange: Introducing SPL-on-FHIR

Details

The U.S. Food and Drug Administration (FDA) is leading a transformative shift in pharmaceutical data handling. Historically, the Structured Product Labeling (SPL) standard relied on HL7 version 3, which suffered from complexity and limited flexibility. To address these limitations, the FDA has advanced its adoption of FHIR. The 'SPL-on-FHIR' initiative aims to replace the outdated V3-based SPL with a modern FHIR-based Implementation Guide (IG). This guide utilizes resources like the 'Medication Definition' introduced in FHIR R5 to structure and exchange comprehensive drug labeling information, including indications, contraindications, and adverse reactions. By leveraging FHIR’s modular architecture and standard terminologies such as SNOMED CT and RxNorm, the FDA is enhancing data quality, consistency, and interoperability. This modernization streamlines both the drug approval process and post-market surveillance, extending FHIR's utility beyond traditional clinical use cases into critical areas of pharmaceutical product information and quality control. The global nature of this industry also necessitates harmonization with international standards.